U. Johansson

发表

CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women.

Å. Borg, H. Jernström, M. Henningson, 2007, Molecular human reproduction.

Breast conserving surgery for invasive breast cancer: Risk factors for ipsilateral breast tumor recurrences

K. Sandelin, L. Rutqvist, A. Mattsson, 1997, Breast Cancer Research and Treatment.

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

H. Johansson, L. Rutqvist, N. Wilking, 2013, European journal of cancer.

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

L. Skoog, J. Lehtiö, B. Linderholm, 2010, Breast Cancer Research and Treatment.

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

H. Johansson, L. Rutqvist, N. Wilking, 1995, Journal of the National Cancer Institute.

Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.

H. Johansson, L. Rutqvist, T. Fornander, 2006, Anticancer research.

Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers

Olaf Johan Hartmann-Johnsen, P. Schrotz-King, C. Ulrich, 2016, Acta oncologica.

CYP 17 genotype is associated with short menstrual cycles , early oral contraceptive use and BRCA mutation status in young healthy women

Å. Borg, H. Jernström, M. Henningson, 2007 .

Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer

H. Jernström, M. Henningson, U. Johansson, 2008, British Journal of Cancer.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

J. Bergh, L. Skoog, G. Elmberger, 2009, Medical oncology.

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

M. King, Å. Borg, O. Johannsson, 1996, American journal of human genetics.

Discordance in hormone receptor status in breast cancer during tumor progression.

J. Bergh, L. Skoog, L. Lindström, 2010 .

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

L. Esserman, J. Hartman, C. Benz, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative fine needle aspiration from human breast cancer is a valuable sampling material for progesterone receptor and cytometric DNA analysis.

M. Fernö, B. Baldetorp, D. Killander, 1996, Acta oncologica.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

J. Bergh, J. Hartman, L. Skoog, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses

M. Fernö, Å. Borg, H. Olsson, 1990 .

BRCA1 and BRCA2 mutation analysis in breast‐ovarian cancer families from northeastern Poland

Å. Borg, J. Limon, U. Johansson, 2003, Human mutation.

Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Å. Borg, N. Loman, O. Johannsson, 1997, American journal of human genetics.

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

L. Skoog, G. Elmberger, R. Lewensohn, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom‐in array comparative genomic hybridization (aCGH)

Å. Borg, J. Staaf, M. Nilbert, 2008, Human mutation.

TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains

E. Hovig, Å. Borg, J. Eyfjörd, 1995, Genes, chromosomes & cancer.

Enzyme immunoassay of progesterone receptor in breast cancer biopsy samples. A comparison with the dextran coated charcoal method.

M. Fernö, Å. Borg, U. Johansson, 1989, Acta oncologica.

Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer.

M. Fernö, Å. Borg, U. Johansson, 1982, Anticancer research.

Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer

J. Bergh, H. Johansson, L. Rutqvist, 2011, Breast Cancer Research and Treatment.

Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma

A. Lindblom, J. Isola, B. Werelius, 2000, International journal of cancer.

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer

A. Hackshaw, M. Baum, T. Fornander, 2009, Journal of the National Cancer Institute.

A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast‐conserving surgery

H. Johansson, L. Rutqvist, U. Johansson, 1998, Cancer.

Uncontrolled local disease after salvage treatment for ipsilateral breast tumour recurrence.

L. Rutqvist, U. Johansson, K. Dalberg, 2003, European Journal of Surgical Oncology.

Biomarkers for local recurrence after breast‐conservation — a nested case‐control study

K. Sandelin, L. Kanter, G. Auer, 1999, Breast Cancer Research and Treatment.

Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group.

M. Fernö, Å. Borg, H. Olsson, 1990, Acta oncologica.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Novel germline p16 mutation in familial malignant melanoma in southern Sweden.

Å. Borg, O. Johannsson, H. Olsson, 1996, Cancer research.